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Available online 2 January 2016AbstractPurpose: To report a case of Wolfram syndrome (WS) characterized by diabetes mellitus, diabetes insipidus, progressive optic atrophy,
and deafness.
Case report: A 19-year-old female patient, a known case of diabetes mellitus type I from six years before, presented with progressive vision loss
since four years earlier. On fundoscopic examination, she had bilateral optic atrophy without diabetic retinopathy. The patient also had diabetes
insipidus, neurosensory deafness, and neurogenic bladder.
Conclusion: WS should be considered a differential diagnosis in patients with diabetes mellitus who present with optic atrophy, and it is
necessary to perform a hearing test as well as collecting 24-h urine output.
Copyright © 2015, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Wolfram syndrome (WS) is an autosomal recessive neuro-
degenerative disorder characterized by Diabetes Insipidus, Dia-
betes Mellitus (non-autoimmune), Optic Atrophy, and Deafness
(a set of conditions referred to as DIDMOAD).1e3 The gene
responsible for the WS, named WSF1, encodes an endoplasmic
reticulum membrane-embedded protein called wolframin that is
expressed in pancreatic beta cells and neurons.4e6 The estimated
prevalence of WS is 1 in 770,000, and it is believed to occur in 1
of 150 patients with type 1 diabetes.6 Affected patients usually
develop insulin-requiring diabetes and optic atrophy in early
childhood, and diabetes insipidus as they become teenagers or
young adults. In WS patients with diabetes insipidus, not only* Corresponding author. Department of Internal Medicine, Imam Khomeini
Hospital, Ardabil University of Medical Sciences, Ardabil, Iran. Tel.: þ98
9163057715.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).does vasopressin neuron loss occur in the supraoptic nucleus, but
there is also a defect in vasopressin precursor processing.7
Anterior pituitary dysfunction has also been reported.6 Other
manifestations of WS include progressive sensorineural deaf-
ness, hydronephrosis (due in part to the high urine flow in dia-
betes insipidus), and neurologic dysfunction.8 Why severe
insulin-requiring diabetes develops is not known; immunologic
factors do not appear to be important.3 Affected individuals have
a median life expectancy of 30 years, with early mortality
credited to neurological disorders, urological abnormalities and
infection.9 There is currently no cure for WS. Differential
diagnosis and treatment are difficult due to the variable pre-
sentation of symptoms.10 In the present study, we report one
patient with WS from Ardabil, Iran.
Case report
A 19-year-old female patient, a known case of type I
diabetes mellitus from six years before, presented to a pri-
vate ophthalmology office. She complained of progressiveosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
Fig. 2. Optic atrophy without diabetic retinopathy in the left eye.
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to 1/10 on both eyes. She had a history of nocturia and high
urine output for five years, and after that, she had inconti-
nency. In the previous two years, she had been avoiding
difficulty and using self-intermittent catheterization four
times a day.
On ophthalmic examination, intraocular pressure was
15 mmHg in both eyes, and biomicroscopic examinations were
completely normal. On fundoscopic examination, she had bilat-
eral optic atrophy without diabetic retinopathy (Figs. 1 and 2).
Accordingly, WS was suspected by the ophthalmologist, who
referred her to an endocrinologist.
Investigations revealed polyuria (14 L per day), hyper-
natremia (156 mEq/L), and hyperglycemia (351 mg/dL). Other
laboratory values were: creatinine, 1.1 mg/dL; urea nitrogen,
28 mg/dL; K, 4.5 mEq/L; TSH, 2.5 mU/L. A random urine
analysis showed a urine specific gravity of 1.006, and the results
of 24-h urine collection obtained a urine specific gravity of
1.005 [normal values: 1.010e1.030]. It was suspected that there
might be an underlying cause for diabetes insipidus, due to the
presence of a low urine specific gravity… Subsequently, a urine
and plasma osmolality was performed, which were 150 and
312 mmol/kg, respectively. These findings suggested a distur-
bance in the regulation of vasopressin. Therefore, a standardized
water deprivation test was done. There was no change either in
urine specific gravity or urine osmolality before and after the
water deprivation test. After nasal desmopressin administration,
urine osmolality increased from 125 mOsm/kg to 600 mOsm/kg
and serum osmolality increased from 281 mOsm/kg to 328Osm/
kg. Given to an increase in urine osmolality of more than 100%
measured by the desmopression stimulation test, the patient was
diagnosed with complete central diabetes insipidus. Treatment
with oral desmopressin was prescribed 100 mcg three times
daily. A few days later, the volume of urine collected in 24 h
was within acceptable range. A Magnetic Resonance Imaging
(MRI) of the brain revealed the loss of the physiologicalFig. 1. Optic atrophy without diabetic retinopathy in the right eye.hyperintense signal of the posterior pituitary gland (bright spot)
on T1-weighted images, suggesting the diagnosis of central
diabetes insipidus (Fig. 3).
An audiologic examination revealed neurosensory deafness,
and audiometry showed a bilateral high-frequency sensori-
neural hearing loss. Renal sonography showed pelvicalyceal
dilatation in both kidneys, equal to hydronephrosis grade II.
The bladder wall had a trabecular pattern, and the urinary tract
was dilated on both sides. The patient had 150 ml post-voiding
bladder residue. Urologic examination and sonographic find-
ings were consistent with a neurogenic bladder.Fig. 3. Magnetic Resonance Imaging (MRI) of the brain revealed the loss of
posterior pituitary bright spot, suggesting the diagnosis of central diabetes
insipidus.
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cooperate for further evaluation.
Discussion
WS was first described in 1938 by Wolfram and Wagener11
as a hereditary syndrome characterized by diabetes mellitus and
optic atrophy acquired early in life. Subsequent reports added
diabetes insipidus and deafness to the syndrome, which develop
in approximately 73 and 62% of sufferers, respectively.3,12
The minimal criteria for diagnosis are juvenile-onset dia-
betes and optic atrophy; however patients also present with
additional complications, hence the acronym DIDMOAD
(Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and
Deafness) is used. The diagnostic criteria for WS are shown
in Table 1. The diagnosis is established in individuals of all
ages in whom two pathological WFS1 or CISD2 mutations are
identified.13
Diabetes mellitus is a key feature of WS, which is usually the
first sign of the disease (median age at diagnosis, 6e15 years),
and optic atrophy (median age at diagnosis 11 years). The mean
age of presentation of diabetes mellitus has been reported to be
5 ± 4 years.14 There are multiple differences between the pre-
sentation and course of autoimmune Type 1 diabetes and dia-
betes of WS. Namely, patients affected with WS have a low
incidence of diabetic ketoacidosis at the time of diagnosis (only
3% compared to 30% in Type 1 diabetes), a much lower insulin
requirement in the first several years after diagnosis, rare
microvascular complications, and rare presence of diabetes an-
tibodies.15 Patients with WS show smaller glycemic variability
than individuals with type 1 diabetes mellitus, and this may be
associated with persistent residual insulin secretion.16
Diabetes insipidus is another component of WS. A loss of
vasopressin-producing neurons in the hypothalamus has been
well documented in this disease and is thought to be the cause
of WS-associated diabetes insipidus.17,18 Neuroradiologists
have reported a loss of signal intensity in the posterior pi-
tuitary, indicating an absence or degeneration of the neuro-
hypophysis18,19; some patients have been found to have
“empty sella”.20
Patients with WS demonstrate progressive ophthalmologic
symptoms that usually occur after diabetes mellitus. Besides
optic atrophy, constriction of visual fields and declined visual
acuity and color vision are the other ophthalmological findingsTable 1
The diagnostic criteria for Wolfram syndrome.
Major criteria Minor criteria
1. Diabetes mellitus <16 yrs,
2. Optic atrophy <16 yrs
1. Diabetes insipidus,
2. Diabetes mellitus >16 yrs,
3. Optic atrophy >16 yrs,
4. sensorineural deafness,
5. Neurological signs (ataxia, epilepsy, neuropa
cognitive impairment),
6. Renal tract abnormalities,
7. 1 loss of function mutation in _WFS1/CISD2
family history of Wolfram syndromein WS21; however, diabetic retinopathy is rarely observed.22
Only five cases with WS have been reported without optic at-
rophy.22 In 2002, Al-Till et al23 performed a study to investi-
gate ophthalmologic abnormalities in fifteen patients with WS.
Of 15 patients with WS reviewed in this study, 93.3% had optic
atrophy, 92.9% had color deficit, 66.6% had cataract, 30% had
pigmentary retinopathy, and 20% had diabetic retinopathy.
Abnormal pupillary light reflexes and nystagmus were also
reported.23 In another study, eye complications were described
in four patients with WS. The ophthalmic signs were a pro-
gressive decrease in visual acuity, constriction of the peripheral
visual field with or without central scotoma, color vision dis-
turbances, and bilateral optic disc atrophy. Diabetic retinopathy
was a rare complication.24 Recently, the retinal thinning has
been proposed as a marker of disease progression in patients
with WS.25
Deafness in WS is commonly a high-frequency, symmetric,
sensorineural hearing loss, usually manifesting in the second or
third decade with a relatively slow rate of deterioration.26,27
Some studies have reported urinary tract abnormalities (hydro-
ureter, urinary incontinence, recurrent infections) in patients
with WS, that these abnormalities are expected in about 66% of
patients. Urinary tract abnormalities include obstruction of the
ureters, an atonic bladder with a large capacity, high pressure
bladder with sphincteric dyssynergia, and incontinence.28 Uri-
nary tract dilatation is presented in 45% of patients with WS,
which may be secondary to chronic high urine flow rate or
neurodegeneration in different levels of the urinary tract.29
Differential diagnosis of WS includes13: (1) Mitochondrial
disorders: Maternally Inherited Diabetes mellitus and Deaf-
ness, Leber Hereditary Optic Neuropathy; (2) Thiamine-
responsive megaloblastic anemia, diabetes, and deafness; (3)
Autosomal Dominant Optic Atrophy; (4) X-linked Charcot-
Marie-Tooth disease type 5; (5) Deafness, Dystonia, Optic
Neuronopathy syndrome; (6) Friedreich ataxia; (7) Bardet-
Biedl syndrome; (8) Alstrom syndrome; and (9) Congenital
rubella syndrome. The association of diabetes mellitus with
optic atrophy also occurs in Friedreich's ataxia, Refsum dis-
ease, Alstrom syndrome, Lawrence-Moon syndrome, Kearn-
Sayre syndrome, and deafness and diabetes in the“3243”
mitochondrial DNA mutation.30
The pathogenesis of the disease remains unknown, but
genetic linkage studies have shown that the mutations of the
WFS1 gene are responsible for the symptoms in 90% of casesMinimum required Other variable suggestive evidence:
thy,
_ AND/OR
2 major
OR
1 major plus 2 minor
criteria
- Hypogonadism (males),
- Absence of type 1 diabetes
auto-antibodies,
- Bilateral cataracts,
- Psychiatric disorder,
- Gastrointestinal disorders
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on the short arm of chromosome 4 (4p16). The WFS1 gene
encodes an 890-amino-acid protein called wolframin, a puta-
tive multispanning membrane glycoprotein of the endoplasmic
reticulum.31 Although no function has yet been ascribed to
wolframin; however, its localization to the endoplasmic re-
ticulum suggests it can play a role in calcium homeostasis,
membrane trafficking and protein processing.32
There is currently no cure for WS, but there are treatments
for some of the features. Diabetes mellitus is treated with in-
sulin, and diabetes insipidus with vasopressin. While hearing
aids can help with hearing loss, there is unfortunately no
treatment for vision loss. Renal problems may be treated by
catheterization (passing a thin, flexible tube into the bladder to
drain away urine), and some of the neurological symptoms can
be treated with medication.29
Based on the findings of the present case, it is highly rec-
ommended that, in patients with diabetes mellitus who have
optimal blood sugar presenting with polyuria and polydipsia, we
need to do urine specific gravity to prove the presence of dia-
betes insipidus. In such patients, performing an ophthalmologic
evaluation can probably reveal this rare disorder of Wolfram
syndrome. In addition, ophthalmologists should be aware that in
patients presenting with diabetes mellitus and optic atrophy
without any signs of diabetic retinopathy, it is necessary to
perform a hearing test as well as collect and analyze 24-h urine
output. Thus, awareness of this condition and timely diagnosis is
important for improving patient prognosis, anticipating associ-
ated complications, and enabling timely genetic counseling for
family members.
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